Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study

被引：0

作者：

Corren, J. ^{[1
]}

Bourdin, A. ^{[2
]}

Chupp, G. ^{[3
]}

Israel, E. ^{[4
]}

Ambrose, C. S. ^{[5
]}

Ackert, J. Llanos ^{[6
]}

Kmita, K. ^{[7
]}

Cook, B. ^{[5
]}

Colice, G. ^{[8
]}

Menzies-Gow, A. ^{[9
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Univ Montpellier, CHU Montpellier, INSERM, PhyMedExp,CNRS, Montpellier, France

[3] Yale Sch Med, New Haven, CT USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Allergy & Immunol, Pulm & Crit Care Med, Boston, MA 02115 USA

[5] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[6] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA

[7] AstraZeneca, BioPharmaceut R&D, Biometr Late Stage Dev Resp & Immunol, Warsaw, Poland

[8] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Gaithersburg, MD USA

[9] Royal Brompton Hosp, London, England

来源：

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A1198

引用

页数：2